Career Mikhail Blagosklonny

Mikhail Blagosklonny

From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Mikhail Blagosklonny
Alma materFirst Pavlov State Medical University of St. Peterburg
Scientific career
FieldsAnti-aging medicine, oncology
Institutions

Mikhail Blagosklonny is a scientist who studies cancer and aging. He is an adjunct faculty member at the Roswell Park Cancer Institute in Buffalo, New York.[1]

Career[edit]

Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Cancer Institute.[2]

Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[3] Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.[4]

https://en.wikipedia.org/wiki/Mikhail_Blagosklonny

Rapamycin and aging[edit]

Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[5] He advocates for rapamycin use in longevity research.[6]

Editorial activities[edit]

Blagosklonny is editor-in-chief of Aging,[7] Cell Cycle,[8] and Oncotarget.[9] In addition, he is associate editor of Cancer Biology & Therapy[10] and a member of the editorial board of Cell Death & Differentiation.[11]

The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,[12] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[13] in July 2015.[12] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[14]

References[edit]

  1. ^ Roswell Park website page on Blagosklonny
  2. ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute", Cancer Biology & Therapy, 8(9): 753–752, May 2009, doi:10.4161/cbt.8.9.8899
  3. ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute". Cancer Biology & Therapy. 8(9): 753–752. May 2009. doi:10.4161/cbt.8.9.8899.
  4. ^ "Mikhail Blagosklonny". Roswell Park Comprehensive Cancer Center. Retrieved 2020-05-01.
  5. ^ Stipp, David (2011). "A New Path to Longevity". Scientific American. 306 (1): 32–39. doi:10.1038/scientificamerican0112-32. PMID 22279832.
  6. ^ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Retrieved November 20, 2016.
  7. ^ "Editorial Board". Aging. Retrieved 2016-11-20.
  8. ^ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20.
  9. ^ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
  10. ^ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
  11. ^ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20.
  12. ^ Jump up to:a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. Archived from the original on 20 April 2016. Retrieved 2016-11-20.
  13. ^ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. Archived from the original on 2 December 2016. Retrieved 19 April 2016.
  14. ^ "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. 6 December 2016. Archived from the original on 24 December 2016. Retrieved 17 January 2017

When people discuss today’s medicine, precision plays one of the most significant roles and people’s lives are directly dependent on it. Hence, any researches related to medicine are necessary to comply with the highest standards. The issue today is that any results of researches can be published online and used as a reference without being precisely checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and attempted to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality indicator. That allows both readers and authors to validate publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication.” Oncotarget website demonstrates a complete publications list with respective scores higher than 100 as well as reports mentioned previously. Mikhail (Misha) Blagosklonny glad to share his new approach and hopes it provides the necessary assistance to anyone, who has interest in oncology.
Zoya Demidenko
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was published back in 2018 by Oncotarget and written by various experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to understand the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output.” Hence, the article about melanoma, was utilized for citations in various news articles 69 times. Besides that, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a brief overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is glad to have the ability to share with online readers this highly appreciated and top-quality information, that is trustworthy and reliable.
Misha Blagosklonny

Comments

  1. AnonymousDecember 22, 2022 at 10:28 PM

    Hey thanks for sharing this amazing content, We also have some amazing content to reduce workplace stress at Resiliency Program

    ReplyDelete

Post a Comment

Popular posts from this blog

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma ABSTRACT Although new analogues of immunomodulatory drugs (IMiDs) are being developed for MM, the molecular mechanism of these drugs remains unclear. In the current study, we used MM cell lines as a model to investigate the molecular mechanism of thalidomide and to compare its potency with IMiDs such as pomalidomide. We determined that thalidomide did not inhibit cell proliferation of RPMI8226 and U266 MM cells, whereas pomalidomide showed a significant inhibitory effect on these two MM cell lines. Interestingly, we further demonstrated that although thalidomide down-regulated bFGF translation through the inhibition of IRES even at 0.1 µg/ml, pomalidomide did not have a similar affect bFGF levels. A colony formation assay demonstrated that thalidomide and the bFGF knock-down clones caused a significant reduction in the clonogenic ability of MM cells, and treatment with exogenous
Read more

The journey of resveratrol from yeast to human

Image
The journey of resveratrol from yeast to human Abstract The natural polyphenolic compound resveratrol was first discovered in the 1940s. In the recent years, this compound received renewed interest as several findings implicated resveratrol as a potent SIRT1 activator capable of mimicking the effects of calorie restriction, and regulating longevity in lower organisms. Given the worldwide increase in age-related metabolic diseases the beneficial effects of resveratrol on metabolism and healthy aging in humans are currently a topic of intense investigation. Resveratrol (3,5,4'-trihydroxystilbene) was first isolated from the roots of white hellebore ( Veratum grandiflorum O. Loes ) in 1940 [ 1 ], and later, in 1963 from the roots of  Polygonum Cupsidatum , a plant used in traditional Chinese and Japanese medicine [ 2 ]. However, the first real interest in this compound came when in 1992 resveratrol was postulated to explain some of the cardio-protective effects of red wine [ 3 ] and w
Read more

DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells

DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells ABSTRACT We investigated the mechanism by which gene silencing of the mTOR inhibitor, DEPTOR, induces cytoreductive effects on multiple myeloma (MM) cells. DEPTOR knockdown resulted in anti-MM effects in several MM cell lines. Using an inducible shRNA to silence DEPTOR, 8226 MM cells underwent TORC1 activation, downregulation of AKT/SGK activity, apoptosis, cell cycle arrest and senescence. These latter cytotoxic effects were prevented by TORC1 paralysis (Raptor knockdown) but not by over-expression of AKT activity. In addition, DEPTOR knockdown-induced MM death was not associated with activation of the unfolded protein response, suggesting that enhanced ER stress did not play a role. In contrast, DEPTOR knockdown in 8226 cells induced p21 expression, independent of p53, and p21 knockdown prevented all of the cytotoxic effects following DEPTOR silencing. DEPTOR silencing resulted in p21 upregulatio
Read more